MARKET

CPIX

CPIX

Cumberland
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.240
-0.050
-1.52%
Closed 16:27 09/23 EDT
OPEN
3.300
PREV CLOSE
3.290
HIGH
3.320
LOW
3.140
VOLUME
15.69K
TURNOVER
--
52 WEEK HIGH
6.10
52 WEEK LOW
3.100
MARKET CAP
49.05M
P/E (TTM)
-7.6795
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Would Shareholders Who Purchased Cumberland Pharmaceuticals' (NASDAQ:CPIX) Stock Three Years Be Happy With The Share price Today?
Investing in stocks inevitably means buying into some companies that perform poorly. But long term Cumberland...
Simply Wall St. · 09/03 13:47
Newly Published Literature Supports Use Of Caldolor® For Postoperative Pain And Reduction Of Opioid Use
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a new review of clinical studies evaluating Caldolor® (ibuprofen) Injection, which was published in the journal Clinical Therapeutics. The manuscript continues an updated integrated safety
PR Newswire · 08/18 13:35
Cumberland Pharma CEO Sends Shareholder, Employee, Partner Letter Following Q2 Results Tues. Evening
https://investor.cumberlandpharma.com/static-files/1ea1ca5d-acd5-4890-993d-a975510fbd91
Benzinga · 08/12 14:44
The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 11:29
Cumberland Q2 EPS $0.08 Beats $0.03 Estimate, Sales $9.60M Beat $9.27M Estimate
Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.03 by 166.67 percent. This is a 20 percent decrease over earnings of $0.10 per share from the same
Benzinga · 08/11 20:30
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 08/11 12:20
Cumberland Pharmaceuticals To Announce Second Quarter 2020 Financial Results
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2020 financial results and Company update after the market closes on Tuesday, Aug. 11, 2020. A conference call and live internet webcast will be held on Tuesday,
PR Newswire · 08/04 20:05
Cumberland Pharmaceuticals Announces Caldolor 'Demonstrates Significant Reduction Of Opioid Use In Orthopedic Trauma Patients'
NASHVILLE, Tenn., July 20, 2020 /PRNewswire/ --Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced the results of a Level 1 Trauma Center study recently
Benzinga · 07/20 12:36
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CPIX. Analyze the recent business situations of Cumberland through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CPIX stock price target is 9.75 with a high estimate of 9.75 and a low estimate of 9.75.
EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 4.16M
% Owned: 27.50%
Shares Outstanding: 15.14M
TypeInstitutionsShares
Increased
8
175.89K
New
8
-150.32K
Decreased
5
557.84K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.52%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Chief Executive Officer/Director
A. Kazimi
Chief Financial Officer
Michael Bonner
Executive Vice President/Director
Martin Cearnal
Executive Vice President
Leo Pavliv
Chief Compliance Officer/Vice President
James Herman
Independent Director
Gordon Bernard
Independent Director
Joseph Galante
Independent Director
Jonathan Griggs
Independent Director
Joey Jacobs
Independent Director
James Jones
Independent Director
Kenneth Krogulski
Independent Director
Caroline Young
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CPIX
Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren (ifetroban) Injection, and Boxaban (ifetroban) oral capsules for the treatment of patients with aspirin-exacerbated respiratory disease (AERD).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cumberland Pharmaceuticals, Inc. stock information, including NASDAQ:CPIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CPIX stock methods without spending real money on the virtual paper trading platform.